Search

Haemonetics Corp

Suletud

SektorTervishoid

84.99 -1.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

85.4

Max

88.27

Põhinäitajad

By Trading Economics

Sissetulek

-65M

-20M

Müük

7.4M

346M

P/E

Sektori keskmine

38.418

64.641

Aktsiakasum

1.29

Kasumimarginaal

-5.817

Töötajad

3,009

EBITDA

-91M

4.3M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

-5.81% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

6. aug 2026

Turustatistika

By TradingEconomics

Turukapital

1.1B

3.6B

Eelmine avamishind

86.6

Eelmine sulgemishind

84.99

Uudiste sentiment

By Acuity

45%

55%

141 / 340 Pingereas Healthcare

Haemonetics Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. aug 2026, 19:56 UTC

Haemonetics Corp shares are higher, reflecting broader market gains amid positive momentum in major tech stocks and easing geopolitical tensions.

31. juuli 2026, 20:04 UTC

Haemonetics Corp shares are higher, with no specific news identified. The broader market has also gained since Thursday's close, recovering from earlier losses.

30. juuli 2026, 19:48 UTC

Haemonetics Corp. shares are lower today, continuing a decline since Wednesday. The stock remains above its 20-day moving average despite recent downward movement.

29. juuli 2026, 21:21 UTC

Haemonetics Corp shares are lower in after-market trading, reflecting broader declines in the equity market and Health Care Supplies sector amid rising oil prices.

28. juuli 2026, 21:01 UTC

Haemonetics Corp shares are lower in after-market hours, following a broader market decline amid a significant drop in the Nikkei 225 Index.

27. juuli 2026, 22:51 UTC

Haemonetics Corp shares are higher in after-market trading, supported by falling crude oil prices and strong performance above the 20-day moving average.

24. juuli 2026, 20:31 UTC

Haemonetics Corp shares are lower in after-market hours, continuing a decline from Friday's close. No specific news was identified to explain the movement.

23. juuli 2026, 23:21 UTC

Haemonetics Corp shares are lower in after-market trading, continuing a decline that began after Thursday's close, reaching the midpoint of their one-month trading range.

22. juuli 2026, 20:13 UTC

Shares of Haemonetics Corp are trading higher in after-market hours, positioned above its 20-day moving average amid broader market volatility and rising crude oil prices.

20. juuli 2026, 18:46 UTC

Haemonetics Corp shares are higher today, continuing gains since Friday's close. The stock reached a session high earlier, though it has pulled back.

Võrdlus sarnastega

Hinnamuutus

Haemonetics Corp Prognoos

Hinnasiht

By TipRanks

-5.81% langus

12 kuu keskmine prognoos

Keskmine 80.57 USD  -5.81%

Kõrge 93 USD

Madal 62 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Haemonetics Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

9 ratings

6

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

141 / 340 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Haemonetics Corp

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
help-icon Live chat